The American Journal of Managed Care

Neoadjuvant Therapy Does Not Increase Morbidity Post Sleeve Lobectomy in NSCLC

A recent study suggests that sleeve lobectomy is safe to perform in patients with non–small cell lung cancer who received neoadjuvant therapy. In patients with non­–small-cell lung cancer (NSCLC) who ...
ascopubs.org

Surgical outcomes of sleeve versus standard lobectomy in patients with non–small cell lung cancer: A systematic review and meta-analysis.

Projected burden of lung cancer and tobacco usage among older adults ≥ 65 in the United States: A CDC WONDER forecasting analysis, 1999–2035. This is an ASCO Meeting Abstract from the 2026 ASCO Annual ...
EurekAlert!

Organ preservation strategies: Extended sleeve lobectomy after neoadjuvant immunochemotherapy offers optimal option for centrally located NSCLC

In this April 2025 issue of Annals of Thoracic Surgery (JCR Q1, IF: 3.6), a retrospective study, led by Professors Jianxing He and Shuben Li from the First Affiliated Hospital of Guangzhou Medical ...
newswise

Study Finds Comparable Response to Adjuvant Chemotherapy/Atezolizumab Following Both Pneumonectomy/Bilobectomy and Lobectomy/Sleeve Lobectomy

Newswise — Boston, MA (May 17, 2022) - IMpower010 was a randomized, multicenter, open-label, phase 3 study done at 227 sites in 22 countries and regions. Eligible patients were 18 years or older with ...